MARKET

BDSI

BDSI

BDSI
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.990
-0.100
-2.45%
After Hours: 4.040 +0.05 +1.25% 17:27 09/17 EDT
OPEN
4.130
PREV CLOSE
4.090
HIGH
4.130
LOW
3.925
VOLUME
2.34M
TURNOVER
--
52 WEEK HIGH
4.990
52 WEEK LOW
3.040
MARKET CAP
393.40M
P/E (TTM)
12.35
1D
5D
1M
3M
1Y
5Y
Top Pharmaceutical Stocks for Q4 2021
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2021.
Investopedia · 3d ago
BioDelivery Sciences International Completes Acquisition of ELYXYB(TM) for Acute Migraine Treatment in the U.S. and Canada
Expands Portfolio and Establishes Growth Platform in Neurology
GlobeNewswire · 09/09 12:30
BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA(R) to Oxycodone at the PAINWeek 2021 Conference
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA (buprenorphine buccal film), CIII at the PAIN...
GlobeNewswire · 09/07 13:28
BioDelivery (BDSI) Up 3.2% Since Last Earnings Report: Can It Continue?
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/03 15:31
5 Buy-Rated Small-Cap Biotech Stocks to Add to Your Watchlist
StockNews.com · 09/03 13:44
BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey, Chief Executive Officer, and Terry Co...
GlobeNewswire · 09/03 12:00
Market Cool On BioDelivery Sciences International, Inc.'s (NASDAQ:BDSI) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 18x, you may...
Simply Wall St. · 09/03 11:55
BioDelivery Sciences International Wins $24M Contract From Department Of Veterans Affairs
https://sam.gov/opp/6178434ed1d74e8db9e008d64f9ecdb0/view
Benzinga · 08/20 16:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BDSI. Analyze the recent business situations of BDSI through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BDSI stock price target is 6.88 with a high estimate of 8.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 213
Institutional Holdings: 71.28M
% Owned: 72.30%
Shares Outstanding: 98.60M
TypeInstitutionsShares
Increased
48
2.93M
New
12
312.27K
Decreased
49
4.50M
Sold Out
20
3.74M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Peter Greenleaf
President
Scott Plesha
Chief Executive Officer/Director
Jeffrey Bailey
Chief Financial Officer/Executive Vice President/Treasurer
Mary Coelho
Senior Vice President
Joseph Lockhart
Senior Vice President
Kevin Ostrander
Chief Compliance Officer/General Counsel/Secretary
James Vollins
Other
Thomas Smith
Director
Mark Sirgo
Independent Director
Todd Davis
Independent Director
Kevin Kotler
Independent Director
Vanila Singh
Independent Director
William Watson
No Data
  • All
  • Financials
  • Insiders
More
About BDSI
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Webull offers kinds of BioDelivery Sciences International, Inc. stock information, including NASDAQ:BDSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDSI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BDSI stock methods without spending real money on the virtual paper trading platform.